A new approach

Activating the immune system
to fight solid tumors.

Anexo Pharma develops treatments
for solid tumors in oncology
and rare diseases.

Activating the immune system
to fight solid tumors.

Anexo Pharma develops treatments
for solid tumors in oncology
and rare diseases.

Developing Programs

AGENT: CyPep-1 // MONOTHERAPY | ALL COMERS | Ph I/II

STATUS: Enrolling | SPONSOR: Anexo Pharma

AGENT: CyPep-1 // MONOTHERAPY | LIVER | Ph I

STATUS: Initiate 2H – 21 | SPONSOR: Anexo Pharma

AGENT: CyPep-1 + Pembrolizumab // COMBINATION | ALL COMERS | Ph I

STATUS: Initiate 2H – 22 | SPONSOR: Anexo Pharma | COLLABORATOR: Merck

AGENT: CyPep-1 + Pembrolizumab // COMBINATION | MELANOMA | Ph II

STATUS: Initiate 2H – 22 | SPONSOR: Anexo Pharma | COLLABORATOR: Merck

AGENT: CyPep-1 + Pembrolizumab // COMBINATION | HNSCC | Ph II

STATUS: Initiate 2H – 22 | SPONSOR: Anexo Pharma | COLLABORATOR: Merck

AGENT: CyPep-1 + Pembrolizumab // COMBINATION | TNBC | Ph II

STATUS: Initiate 2H – 22 | SPONSOR: Anexo Pharma | COLLABORATOR: Merck

AGENT: CYPEP-1 // MONOTHERAPY | RECURRENT RESPIRATORY PAPILLOMATOSIS | PH I/II

STATUS: Initiate 2H – 22 | SPONSOR: Anexo Pharma